Cargando…

Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report

Patients treated with immune checkpoint inhibitors (ICIS) are prone to immune related adverse events (irAEs), making it important to pay attention to these adverse events. Herein, we report a case of onychopathy after treatment of extensive small cell lung cancer (ES-SCLC) with durvalumab; this is t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Cuifen, Wang, Ke, Zhang, Hong, Liu, Jingjing, Zheng, Chuangjie, Tao, Jiahao, Lin, Lizhu, Zhai, Linzhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492564/ https://www.ncbi.nlm.nih.gov/pubmed/37694194 http://dx.doi.org/10.2147/CCID.S415119

Ejemplares similares

First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis
por: Tao, Jiahao, et al.
Publicado: (2022)

Development and External Validation of a Nomogram to Predict Cancer-Specific Survival in Patients with Primary Intestinal Non-Hodgkin Lymphomas
por: Zhang, Cuifen, et al.
Publicado: (2021)

The impact of surgery on long-term survival of patients with primary intestinal non-Hodgkin lymphomas based on SEER database
por: Zhang, Cuifen, et al.
Publicado: (2021)

Current clinico-mycological trends of onychopathies in Casablanca
por: Badaoui, L, et al.
Publicado: (2014)

Onychopathy Induced by Nivolumab: A Targeted Immunotherapy
por: Zahoor, Fatima, et al.
Publicado: (2022)

Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
por: Wang, Lan, et al.
Publicado: (2021)

Case Report: Durvalumab-Associated Encephalitis in Extensive-Stage Small Cell Lung Carcinoma
por: Shionoya, Yosuke, et al.
Publicado: (2021)

Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome
por: Machiyama, Hirotomo, et al.
Publicado: (2023)

Trastuzumab–Docetaxel Combination Chemotherapy Induced Severe Onychopathy
por: Sonthalia, Sidharth, et al.
Publicado: (2017)

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Correction to: Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Surgical therapy and survival in young patients with stage I–II hepatocellular carcinoma: a retrospective cohort study
por: Zhang, Cuifen, et al.
Publicado: (2022)

The Impact of Onychopathies on Quality of Life: A Hospital-based, Cross-sectional Study
por: Tabassum, Hera, et al.
Publicado: (2020)

Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report
por: Liu, Wenhui, et al.
Publicado: (2022)

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
por: Li, Lijuan, et al.
Publicado: (2023)

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
por: Hotta, Katsuyuki, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
por: Ionova, Yelena, et al.
Publicado: (2022)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
por: Zhang, Longfeng, et al.
Publicado: (2020)

A novel predictive factor for the onset time of docetaxel-induced onychopathy: a multicenter retrospective study
por: Takahata, Hidenobu, et al.
Publicado: (2016)

The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data
por: Wang, Bi-Cheng, et al.
Publicado: (2023)

Functional drug–target–disease network analysis of gene–phenotype connectivity for curcumin in hepatocellular carcinoma
por: Zhao, Yuanyuan, et al.
Publicado: (2021)

Case Report: Limbic encephalitis following treatment with durvalumab for small-cell lung cancer
por: Moss, Thomas T., et al.
Publicado: (2023)

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
por: Boys, Emma, et al.
Publicado: (2023)

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
por: Preti, Beatrice T. B., et al.
Publicado: (2023)

Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
por: Botticella, Angela, et al.
Publicado: (2019)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
por: Chu, Chia‐Hsun, et al.
Publicado: (2020)

Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
por: Zheng, Jieling, et al.
Publicado: (2022)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
por: Paz-Ares, L., et al.
Publicado: (2022)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)
por: Ishii, Hidenobu, et al.
Publicado: (2022)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
por: Melillo, Giovanni, et al.
Publicado: (2021)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

Cost‐effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non‐small cell lung cancer
por: Buja, Alessandra, et al.
Publicado: (2022)

Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
por: Patel, Shivani, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6qfmbj97i7dnmefroshikfaftn